How Strong Is AbbVie's Immunology Franchise After Humira's LOE?

Key Takeaways AbbVie's Skyrizi and Rinvoq sales rose 53% to $18.5B so far in 2025, fueling a strong post-Humira recovery.Robust volume gains and expanding indications support AbbVie's momentum across key IBD markets.AbbVie sees combined Skyrizi and Rinvoq sales topping $25B in 2025 and surpassing $31B by 2027.AbbVie (ABBV) is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the compan ...